Overactive bladder/enuresis:
Indications for VESICARE:
Overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Adult Dosage:
Swallow whole with water. Initially 5mg once daily; if well tolerated, may increase to 10mg once daily. Severe renal impairment (CrCl<30mL/min), moderate hepatic impairment (Child-Pugh B), or concomitant potent CYP3A4 inhibitors: max 5mg once daily.
Children Dosage:
Not established.
VESICARE Contraindications:
Gastric or urinary retention. Uncontrolled narrow-angle glaucoma.
VESICARE Warnings/Precautions:
Significant bladder outlet obstruction, decreased GI motility, high risk or history of QT prolongation, severe hepatic impairment: not recommended. Controlled narrow-angle glaucoma. Monitor for CNS effects esp. after initiation or dose increases; consider dose reduction or discontinuation if occurs. Severe renal or moderate hepatic impairment (see Adult dose). Exposure to high environmental temperature. Pregnancy. Nursing mothers.
VESICARE Classification:
Muscarinic antagonist.
VESICARE Interactions:
Potentiated by potent CYP3A4 inhibitors (eg, ketoconazole); see Adult dose. May be antagonized by CYP3A4 inducers. Avoid drugs known to prolong the QT interval. Additive anticholinergic effects with other anticholinergics.
Adverse Reactions:
Dry mouth, constipation, UTI, blurred vision; angioedema (discontinue if occurs), CNS effects (eg, headache, confusion, hallucination, somnolence); rare: anaphylactic reactions.
Generic Drug Availability:
NO
How Supplied:
Tabs—30, 90
